InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.033 -0.007 (-17.50%)+
Announcement
Release
26 Feb 2026 6:12PM
Price at Release
$0.040
Full Release
download
Summary
Patrys Limited, an Australian biotechnology company, reported a comprehensive loss of $3,021,202 for the half-year ended 31 December 2025, a significant increase from the loss of $1,520,310 in the previous year. During this period, Patrys did not lodge any R&D claims due to its ongoing restructuring and did not engage in substantive research activities. The company's cash balance increased to $1,903,841 from $742,441 as of 30 June 2025. The company undertook several capital raising activities, including an entitlement offer and a share consolidation of 15:1. Throughout this period, Patrys focused on strategic initiatives such as acquiring Reliis Pty Ltd and expanding its portfolio with the CNS therapeutic asset RLS-2201. Additionally, the company did not declare or pay any dividends during this half-year.
Key Points
  • Patrys Limited reported a loss of $3,021,202 for the half-year ended 31 December 2025.
  • The company did not lodge any R&D claims during this period.
  • Cash balance as of 31 December 2025 was $1,903,841.
  • Capital raising activities included an entitlement offer and a 15:1 share consolidation.
  • Acquisition of Reliis Pty Ltd introduced a CNS therapeutic asset, RLS-2201.
  • No dividends were declared or paid during the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.